Dr. George A Karpouzas, MD
Claim this profileThe Lundquist Institute at Harbor-UCLA Medical Center
Studies Lupus
Studies Juvenile Idiopathic Arthritis
7 reported clinical trials
20 drugs studied
Affiliated Hospitals
Clinical Trials George A Karpouzas, MD is currently running
Litifilimab
for Lupus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: - How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), and the Patient Global Assessment - Visual Analog Scale (PGA-VAS). Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.
Recruiting1 award Phase 3
M5049
for Lupus
This trial involves taking a pill called M5049. It targets patients with specific types of lupus who have already been treated for several months. The goal is to check if the pill is safe and works well over a longer time.
Recruiting0 awards Phase 22 criteria
More about George A Karpouzas, MD
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments George A Karpouzas, MD has experience with
- Placebo
- Monthly Healthcare Coordinator Calls
- Multidisciplinary Rheumatologic Care
- Nurse Education And Monthly Calls
- Rheumatoid Arthritis Educational Booklet
- Technology-based Symptom Monitoring And Reporting
Breakdown of trials George A Karpouzas, MD has run
Juvenile Idiopathic Arthritis
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
- Multidisciplinary Care for Rheumatoid Arthritis
Arthritis
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
- Multidisciplinary Care for Rheumatoid Arthritis
Rheumatoid Arthritis
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
- Multidisciplinary Care for Rheumatoid Arthritis
Lupus Nephritis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does George A Karpouzas, MD specialize in?
George A Karpouzas, MD focuses on Lupus and Juvenile Idiopathic Arthritis. In particular, much of their work with Lupus has involved treating patients, or patients who are undergoing treatment.
Is George A Karpouzas, MD currently recruiting for clinical trials?
Yes, George A Karpouzas, MD is currently recruiting for 2 clinical trials in Torrance California. If you're interested in participating, you should apply.
Are there any treatments that George A Karpouzas, MD has studied deeply?
Yes, George A Karpouzas, MD has studied treatments such as Placebo, Monthly healthcare coordinator calls, Multidisciplinary rheumatologic care.
What is the best way to schedule an appointment with George A Karpouzas, MD?
Apply for one of the trials that George A Karpouzas, MD is conducting.
What is the office address of George A Karpouzas, MD?
The office of George A Karpouzas, MD is located at: The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California 90502 United States. This is the address for their practice at the The Lundquist Institute at Harbor-UCLA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.